68Ga-NOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor), for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Human

Trial Profile

68Ga-NOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor), for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Human

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Gallium-68 NOTA AE105 (Primary)
  • Indications Bladder cancer; Breast cancer; Prostate cancer
  • Focus Adverse reactions; Diagnostic use; First in man
  • Acronyms uPAR-PET
  • Most Recent Events

    • 21 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top